. 2015 Nov 18;53(12):3853–3858. doi: 10.1128/JCM.02392-15

TABLE 2.

Discordant DBS test results

Sample	Patient age (mo)	Oblast	AmpliSens whole-blood test result	DBS test result^a
Sample	Patient age (mo)	Oblast	AmpliSens whole-blood test result	Abbott Qualitative^b	AmpliSens^c	Roche CAP/CTM^d
1	7	Crimean	Negative^e	Negative	Negative	Positive, C_T of >34
2	5	Kiev	Positive^f	Negative	Positive, C_T of 35	Positive, C_T of >34
3	3	Dnipropetrovsk	Positive^f	Negative	Positive, C_T of >35	Negative
4	14	Dnipropetrovsk	Positive^f	Negative	Positive, C_T of 33	Positive, C_T of >34
5	4	Donetsk	Positive^f	Positive^g	Negative	Positive, C_T of >34
6	6	Odessa	Positive^f	Negative	Positive, C_T of 34	Positive, C_T of >34

DBS, dried blood spot; C_T, cycle threshold.

Abbott Laboratories (Abbott Molecular, Inc., Des Plaines, IL, USA).

Federal Budget Institute of Science, Central Research Institute for Epidemiology (Moscow, Russia).

Roche Molecular Systems, Inc. (Branchburg, NJ, USA).

Confirmed by an ELISA (Ani Labsystems Ltd., Finland) and the Genscreen Ultra HIV Ag-Ab test (Bio-Rad, France).

Confirmed by the Abbott HIV Viral Load test.

The C_T value was not provided by the Abbott test software, but the amplification curve indicated a weak positive result.